Risk factors for pelvic and para-aortic lymph node metastasis in endometrial cancer: A retrospective analysis of 284 patients

Aim: Hysterectomy is generally used to treat patients with endometrial cancer. Although lymphadenectomy can provide prognosticinformation, there are serious complications that can result from lymph node dissection. In order to avoid unnecessary surgicalintervention, predictors related to both pelvic and para-aortic lymph node metastasis can be identified. In this study, we sought todefine independent prognosticators for pelvic and para-aortic lymph node metastasis in women with endometrial cancer.Material and Methods: In total, 284 patients who were treated surgically between December 2009 and January 2019 were includedin the study. The relationships between histopathological patient characteristics and definitive lymph node status were studied.Results: In multivariate analysis, lymphovascular space invasion (Adjusted Odds Ratio: 4.8, 95% Confidence Interval 2.4–17.5,p = 0.001) and deep myometrial invasion (Adjusted Odds Ratio 3.8, 95% Confidence Interval 1.1–14.3) were independent factorsfor pelvic lymph node metastasis. In multivariate analysis for para-aortic lymph node metastasis, lymphovascular space invasion(Adjusted Odds Ratio 5.9, 95% Confidence Interval 2.1–10.3) and pelvic lymph node metastasis (Adjusted Odds Ratio 20.8, 95%Confidence Interval 8.9–32.3) were independent prognostic factors significantly associated with the presence of para-aortic lymphnode metastasis.Conclusion: The two independent histopathological factors identified for predicting the presence of pelvic lymph node metastasiswere lymphovascular space invasion and outer half myometrial penetration of the tumor. Lymphovascular space invasion and pelviclymph node metastasis were independently associated with the presence of para-aortic lymph node metastasis. Consideration oflymphadenectomy in patients who have evidence of outer half myometrial invasion or pelvic lymph node metastasis on preoperativeimaging may be prudent. Lymphovascular space invasion and myometrial invasion findings on frozen section can be used beforeproceeding with lymphadenectomy in endometrial cancer.

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7.
2. Kimura T, Kamiura S, Yamamoto T et al. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet 2004;85:145.
3. American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413.
4. Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707.
5. ASTEC study group, Kitchener H, Swart AM, Qian Q et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36.
6. Turkmen O, Tasci T, Basaran D et al. Stage IB Endometrioid Type Endometrial Cancer: The Role of Lymphadenectomy and Adjuvant Radiation Therapy. Gynecol Obstet Reprod Med 2018;24:156-61.
7. Chan JK, Cheung MK, Huh WK et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107:1823-30.
8. Frost JA, Webster KE, Bryant A et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Systematic Rev 2017;10:7585.
9. Karalok A, Turan T, Basaran D et al. Lymph node metastasis in patients with endometrioid endometrial cancer: overtreatment is the main issue. Int J Gynecol 2017;27:748–53.
10. Kodama S, Kase H, Tanaka K et al. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 1996;53:23-30.
11. Cragun JM, Havrilesky LJ, Calingaert B et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.J Clin Oncol 2005;23:3668-75.
12. Chan JK, Cheung MK, Huh WK et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients.Cancer 2006;107:1823-30.
13. Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29-33.
14. Todo Y, Yamamoto R, Minobe S et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 2010;119:60.
15. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889–92.
16. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103.
17. Turan T, Ureyen I, Duzguner I et al. Analysis of patients with stage IIIC endometrial cancer. Int J Gynecol Cancer 2014;24:1033–41.
18. Sari ME, Yalcin I, Sahin H et al. Risk factors for paraaortic lymph node metastasis in endometrial cancer. Int J Clin Oncol 2017;22:937–44.
19. Lee J, Kong TW, Paek J et al. Predicting model of lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer. Int J Gynecol 2016; 26:1630–35.
20. Benedetti Panici P, Basile S et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in earlystage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707–16.
21. Holloway RW, Abu-Rustum NR, Backes FJ et al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017;146:405.
22. Lago V, Martín B, Ballesteros E et al. Tumor Grade Correlation Between Preoperative Biopsy and Final Surgical Specimen in Endometrial Cancer: The Use of Different Diagnostic Methods and Analysis of Associated Factors.Int J Gynecol Cancer 2018;28:1258-63.
23. Li Y, Cong P, Wang P et al. Risk factors for pelvic lymph node metastasis in endometrial cancer. Arch Gynecol Obstet 2019;300:1007-13.
24. Mariani A, Webb MJ, Keeney GL et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000;182:1506– 19.
25. Vargas R, Rauh-Hain JA, Clemmer J et al. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol 2014;133:216- 20.
26. Kumar S, Podratz KC, Bakkum-Gamez JN. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol 2014;132:38-43.